Kineta, Inc. (KA) Long-Term Liabilities to Capital

Kineta, Inc. (KA) focuses on creating innovative drugs that suppress tumor resistance and stimulate the body's defensive functions. The development of advanced anti-cancer molecules is backed by patents, ensuring a prolonged period of intellectual property capitalization. The business model relies on the full outsourcing of clinical trials to external contractors under strict management control. The price trajectory of the asset with the 0.00 indicator is shown below.

Kineta, Inc. develops innovative immunotherapeutic agents to combat tumor resistance. The long-term debt-to-equity ratio quantifies the company's reliance on external borrowing in the absence of current sales. This metric determines the proportion of loans with maturities exceeding one year, assessing the issuer's financial stability. Low leverage minimizes bankruptcy risk but limits the pace of expansion. An analysis of the long-term debt-to-net assets ratio on GURU.Markets reveals the true liquidity dynamics of the business.